DEA Again Bumps Up 2022 Production Quotas for Psyc
Post# of 160
(Total Views: 373)
Posted On: 12/10/2021 5:19:11 PM
DEA Again Bumps Up 2022 Production Quotas for Psychedelics
In a notice that was recently published in the Federal Register, the Drug Enforcement Agency (“DEA”) revised upwards its 2022 quota for the production of illicit controlled substances, such as DMT, MDMA and psilocybin, for research purposes. The agency adjusted its quota once again for these psychedelic substances, in response to the increased demand and interest in the scientific community.
When it first released its quota for the year, psilocybin’s production quota was 30 grams. This number has now grown to 8,000 grams, which is more than a 26,000% increase. In its statement, the DEA stated that the aggregate production quotas reflected its estimates of the industrial, research, scientific and medical needs of the United States next year.
The agency noted that it would adjust the quotas if the needs changed, explaining that if it received additional quota applications from manufacturers registered under the DEA or received additional research protocols for researchers registered under the DEA, it would consider revising the production quotas yet again.
For MDMA, the agency’s production quota has grown from 3,200 grams to more than 8,000 grams. This is quite an increase from its initial 2021 quota of 50 grams. Its 2022 quota for DMT, which is another drug of interest within the medical and research communities, grew to 3,000 grams from 250 grams. Its initial 2021 quota for the drug stood at 50 grams.
In the notice, the DEA stated that it had received feedback from indigenous communities on the production of specific substances that are utilized in ceremonies. This included feedback from the Native American Church of North America, which centered on mescaline. Mescaline is found in a small spineless cactus known as peyote, which contain various psychoactive alkaloids.
The Native American Church of North America stated that the peyote ceremonies it conducted depended on the availability of peyote, explaining that the non-native use of this particular substance in clinical studies and research would directly affect the church’s ability to possess, use, transport and purchase the substance. The church added that its use in research would also result in the commercialization and exploitation of peyote and possible reclassification of the substance under the Controlled Substances Act.
In its response, the DEA noted that it would not propose the manufacture of mescaline derived from peyote and would instead rely on the substance’s synthetic forms. The agency also ended a monopoly on federally authorized marijuana manufacturing, which will make it easier to meet its 3.2 million-gram production quota for marijuana.
As more entities conduct research on psychedelic substances, the therapeutic formulations developed by companies such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) will have plenty of literature backing them up.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
In a notice that was recently published in the Federal Register, the Drug Enforcement Agency (“DEA”) revised upwards its 2022 quota for the production of illicit controlled substances, such as DMT, MDMA and psilocybin, for research purposes. The agency adjusted its quota once again for these psychedelic substances, in response to the increased demand and interest in the scientific community.
When it first released its quota for the year, psilocybin’s production quota was 30 grams. This number has now grown to 8,000 grams, which is more than a 26,000% increase. In its statement, the DEA stated that the aggregate production quotas reflected its estimates of the industrial, research, scientific and medical needs of the United States next year.
The agency noted that it would adjust the quotas if the needs changed, explaining that if it received additional quota applications from manufacturers registered under the DEA or received additional research protocols for researchers registered under the DEA, it would consider revising the production quotas yet again.
For MDMA, the agency’s production quota has grown from 3,200 grams to more than 8,000 grams. This is quite an increase from its initial 2021 quota of 50 grams. Its 2022 quota for DMT, which is another drug of interest within the medical and research communities, grew to 3,000 grams from 250 grams. Its initial 2021 quota for the drug stood at 50 grams.
In the notice, the DEA stated that it had received feedback from indigenous communities on the production of specific substances that are utilized in ceremonies. This included feedback from the Native American Church of North America, which centered on mescaline. Mescaline is found in a small spineless cactus known as peyote, which contain various psychoactive alkaloids.
The Native American Church of North America stated that the peyote ceremonies it conducted depended on the availability of peyote, explaining that the non-native use of this particular substance in clinical studies and research would directly affect the church’s ability to possess, use, transport and purchase the substance. The church added that its use in research would also result in the commercialization and exploitation of peyote and possible reclassification of the substance under the Controlled Substances Act.
In its response, the DEA noted that it would not propose the manufacture of mescaline derived from peyote and would instead rely on the substance’s synthetic forms. The agency also ended a monopoly on federally authorized marijuana manufacturing, which will make it easier to meet its 3.2 million-gram production quota for marijuana.
As more entities conduct research on psychedelic substances, the therapeutic formulations developed by companies such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) will have plenty of literature backing them up.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
(0)
(0)